Lilly 4Q Revenues: $5.6 billion (+7%) 4Q Earnings:  $771.8 million (+61%) FY Revenues: $21.2 billion (+6%) FY Earnings: $2.7 billion (+14%) Comments: Growth for the year was primarily driven by Trulicity ($926 million, up from $249 million FY15) and other new pharmaceutical products, including Cyramza ($614 million up 60%), Jardiance ($202 million, up from $60 million FY15) and Taltz ($113 million), as well as Humalog ($2.8 billion, down 3%) and Erbitux ($687 million, up 42%, due ...